Regenerative Medicine and Stem Cells Partnering Terms and Agreements:Industry Analysis Report @ http://www.researchmoz.us/regenerative-medicine-and-stem-cells-partnering-terms-and-agreements-report.html

1. Regenerative Medicine and Stem Cells Partnering Terms and Agreements
The Regenerative Medicine and Stem Cells Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the
Regenerative medicine and Stem cells partnering deals and agreements entered into by the worlds leading healthcare companies. Trends in regenerative
medicine and stem cells deals Deal terms analysis Partnering agreement structure Partnering contract documents Top deals by value Most active dealmakers
Average deal terms for regenerative medicine and stem cells The report provides a detailed understanding and analysis of how and why companies enter
regenerative medicine and stem cells partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to
license the licensors regenerative medicine and stem cells technology. These deals tend to be multicomponent, starting with collaborative R&D, and
commercialization of outcomes. This report provides details of the latest regenerative medicine and stem cells agreements including cell therapy agreements
announced in the healthcare sector. Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the
negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the
payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and
databases do not.
This report contains a comprehensive listing of all regenerative medicine and stem cells partnering deals announced since
2009 including financial terms where available including over 650 links to online deal records as disclosed by the deal parties. In addition, where available,
records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the
answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact
on each party’s ability to derive value from the deal. For example, analyzing actual company deals and agreements allows assessment of the following:
What is actually granted by the agreement to the partner company? What exclusivity is granted? What are the precise rights granted or optioned? What is the
payment structure for the deal? How aresalesand payments audited? What is the deal term? How are the key terms of the agreement defined? How are IPRs
handled and owned? Who is responsible for commercialization? Who is responsible for development, supply, and manufacture? How is confidentiality and
publication managed? How are disputes to be resolved? Under what conditions can the deal be terminated? What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed? Which boilerplate clauses does the company insist upon? Which boilerplate clauses appear to
differ from partner to partner or deal type to deal type? Which jurisdiction does the company insist upon for agreement law? The initial chapters of this report
provide an orientation of drug dealmaking and business activities.
Chapter 1 provides an introduction to the report, whilst
Chapter 2 provides an overview of the trends in regenerative medicine and stem cells dealmaking since 2009, including details of average headline, upfront,
milestone and royalty terms.
Chapter 3 provides a review of the leading regenerative medicine and stem cells deals since 2009. Deals are listed by
headline value, signed by bigpharma, most active bigpharma, and most active of all biopharma companies. Where the deal has an agreement contract published at
the SEC a link provides online access to the contract. Chapter 4 provides a comprehensive listing of the top 50 bigpharma companies with a brief summary
followed by a comprehensive listing of regenerative medicine and stem cells deals, as well as contract documents available in the public domain. Where
available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of regenerative medicine and stem cells partnering deals signed and announced since 2009, where a
contract document is available in the public domain. The chapter is organized by stage of development at signing, deal type (collaborative R&D, co-promotion,
licensing etc), specific therapy focus and specific technology type . Each deal title links via Weblink to an online version of the deal record and where available,
the contract document, providing easy access to each contract document on demand. The report also includes numerous tables and figures that illustrate the
trends and activities in regenerative medicine and stem cells partnering and dealmaking since 2009. In addition, a comprehensive appendix is provided
organized by regenerative medicine and stem cells partnering company A-Z , deal type definitions and regenerative medicine and stem cells partnering
agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access
to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know
about partnering in the research, development and commercialization of regenerative medicine and stem cells technologies and products.
Regenerative Medicine and Stem Cells Partnering Terms and Agreements provides the reader with the following key benefits: In-depth understanding of
regenerative medicine and stem cells deal trends since 2009 Access to headline, upfront, milestone and royalty data Analysis of the structure of regenerative
medicine and stem cells agreements with numerous real life case studies Comprehensive access to actual regenerative medicine and stem cells contracts entered
into by the world’s biopharma companies Detailed access to actual regenerative medicine and stem cells contracts enter into by the leading fifty big
pharma companies Insight into the terms included in a regenerative medicine and stem cells agreement, together with real world clause examples Understand the
key deal terms companies have agreed in previous deals Undertake due diligence to assess suitability of your proposed deal terms for partner companies
table Of Content
executive Summary
chapter 1 – Introduction
chapter 2 – Trends In Regenerative Medicine And Stem Cells Dealmaking
2.1. Introduction
2.2. Regenerative Medicine And Stem Cells Partnering Over The Years
2.3. Big Pharma Regenerative Medicine And Stem Cells Dealmaking Activity
2.5. Most Active In Regenerative Medicine And Stem Cells Partnering
2.6. Regenerative Medicine And Stem Cells Partnering By Deal Type
2.7. Regenerative Medicine And Stem Cells Partnering By Disease Type
2.8. Partnering By Regenerative Medicine And Stem Cells Technology Type
2.9. Average Deal Terms For Regenerative Medicine And Stem Cells Partnering
2.9.1 Regenerative Medicine And Stem Cells Headline Values
2.9.2 Regenerative Medicine And Stem Cells Upfront Payments
2.9.3 Regenerative Medicine And Stem Cells Milestone Payments
Regenerative Medicine and Stem Cells Partnering Terms and Agreements

2. 2.9.4 Regenerative Medicine And Stem Cells Royalty Rates
2.10. The Anatomy Of Regenerative Medicine And Stem Cells Partnering
2.10. The Anatomy Of A Regenerative Medicine And Stem Cells Deal
2.10.a. Case Study 1: Oregon Health & Science University- Regen Biopharma- June 2012
2.10.b. Case Study 2: Thermogenesis- Nanshan Memorial Medical Institute- November 2010
2.10.c. Case Study 3: Ascent Therapeutics- Bioheart- January 2010
chapter 3 – Leading Regenerative Medicine And Stem Cells Deals
3.1. Introduction
3.2. Top Regenerative Medicine And Stem Cells Deals By Value
chapter 4 – Bigpharma Regenerative Medicine And Stem Cells Deals
4.1. Introduction
4.2. How To Use Bigpharma Regenerative Medicine And Stem Cells Partnering Deals
4.3. Bigpharma Regenerative Medicine And Stem Cells Partnering Company Profiles
chapter 5 – Regenerative Medicine And Stem Cells Partnering Contracts Directory
5.1. Introduction
5.2. Company A-z
5.3. By Deal Type
5.4. By Stage Of Development
5.5. By Therapy Area
chapter 6 – Regenerative Medicine And Stem Cells Dealmaking By Technology Type
6.1. Introduction
6.2. Deals By Cell Therapy, Regenerative Medicine And Stem Cells Type
appendices
introduction
appendix 1 – Directory Of Regenerative Medicine And Stem Cells Deals By Company A-z 2009-2013
appendix 2 – Directory Of Regenerative Medicine And Stem Cells Deals By Stage Of Development 2009-2013
discovery
formulation
marketed
phase I
phase Ii
phase Iii
preclinical
regulatory
appendix 3 – Directory Of Regenerative Medicine And Stem Cells Deals By Deal Type 2009-2013
asset Purchase
bigpharma Outlicensing
co-development
collaborative R&d
co-market
contract Service
co-promotion
crada
cross-licensing
development
distribution
equity Purchase
evaluation
grant
interests
joint Venture
licensing
litigation
Regenerative Medicine and Stem Cells Partnering Terms and Agreements

3. manufacturing
marketing
material Transfer
option
promotion
research
settlement
spin Out
sub-license
supply
technology Transfer
termination
warranty
appendix 4 – Directory Of Regenerative Medicine And Stem Cells Deals By Therapy Area 2009-2013
cardiovascular
central Nervous System
dental
dermatology
gastrointestinal
genetic Disorders
genitourinary
hematology
hospital Care
immunology
infectives
metabolic
musculoskeletal
obstetrics
oncology
ophthalmics
pediatrics
respiratory
appendix 5 – Regenerative Medicine And Stem Cells Partnering Resource Center
online Regenerative Medicine And Stem Cells Partnering
regenerative Medicine And Stem Cells Partnering Events
further Reading On Regenerative Medicine And Stem Cells Dealmaking
about Wildwood Ventures
current Partnering
current Agreements
recent Titles From Currentpartnering
order Form – Reports
ResearchMoz(http://www.researchmoz.us/) is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your
research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and
across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an
informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
Contact:
M/s Sheela,
90 State Street,
Suite 700,
Albany NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Regenerative Medicine and Stem Cells Partnering Terms and Agreements